MREO

MREO

USD

Mereo BioPharma Group plc American Depositary Shares

$1.780-0.050 (-2.732%)

Prix en Temps Réel

Healthcare
Biotechnologie
Royaume-Uni

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$1.830

Haut

$1.880

Bas

$1.780

Volume

1.12M

Fondamentaux de l'Entreprise

Capitalisation Boursière

283.2M

Industrie

Biotechnologie

Pays

United Kingdom

Statistiques de Trading

Volume Moyen

1.32M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $1.47Actuel $1.780Haut $4.395

Actualités Connexes

PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

Voir plus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
Analyst Upgrades

JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8

JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group with a Overweight and raises the price target from $7 to $8.

Voir plus
JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

Voir plus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
BusinessWire

āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2

- Company's second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - - āshibio has exclusive license to develop and commercialize vantictumab

Voir plus
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
GlobeNewswire

Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights

Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta expected around year-end 2025 Cash of $56.1 million as of June 30, 2025, expected to support operations into 2027 LONDON, Aug. 12,

Voir plus
Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors...

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.